|
1
|
Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. J Hypertens 2013; 31:993-1000. [DOI: 10.1097/hjh.0b013e32835f5721] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
|
2
|
Sarafidis PA, Ruilope LM. Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression. J Renin Angiotensin Aldosterone Syst 2012; 13:217-9. [DOI: 10.1177/1470320312439140] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Drugs suppressing the renin-angiotensin-aldosterone system (RAAS) are now widely used to treat patients all along the cardiorenal continuum. It supposes that many patients, in particular those with arterial hypertension are treated with converting-enzyme inhibitors and angiotensin receptor blockers for years during which the development and prograssion of cardiorenal disease can be observed. The meaning of this progression in the presence of RAAS suppression requires to be clarified and to be treated in order to diminish the velocity of progression of cardiorenal disease.
Collapse
Affiliation(s)
| | - Luis M Ruilope
- Hypertension Unit, Hospital 12 de Octubre and Department of Preventive Medicine and Public Health, University Autonoma, Madrid, Spain
| |
Collapse
|
|
3
|
Current World Literature. Curr Opin Nephrol Hypertens 2011; 20:561-7. [DOI: 10.1097/mnh.0b013e32834a3de5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|